Dyadic International announces publication on study of C1 monoclonal antibody

Dyadic International announced the online publication of the manuscript “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models” in Nature Communications, an international journal publishing peer-reviewed research in all fields of science and technology. “These results demonstrate that the C1-expression system is promising as a technology platform for human monoclonal antibody development and production for preventive and therapeutic medicines,” said Prof. Albert Osterhaus of Hannover University of Veterinary Medicine, Germany and of CR2O, a Dutch CRO. “The study characterized the in vitro activity of a monoclonal antibody produced by C1 cells and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication. Those are significant findings, in the sense that the demonstration of HuMab 87G7 in animal models against SARS-CoV-2 provided protection, especially with the raising concerns related to emerging infectious diseases in a changing world.”